Evidence map›Paper›PMID 35657562›Full record

ReviewHuman cell2022

ATP-gated P2X7 receptor as a potential target for prostate cancer.

Cuicui Qiao, Yiqing Tang, Qianqian Li, Xiaodi Zhu, Xiaoxiang Peng, Ronglan Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Human cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cuicui QiaoSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Yiqing TangSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Qianqian LiSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Xiaodi ZhuSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Xiaoxiang PengSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Ronglan ZhaoSchool of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China. zhaoronglan76@sina.com.ORCID http://orcid.org/0000-0002-4302-2563
Weifang Medical University · CN

Funding

National Natural Science Foundation of China no. 81301737National Natural Science Foundation of China no. 81770915Shandong Provincial Natural Science Foundation no. ZR2021MH306
6 · The paper itself

Abstract

Prostate cancer is the most common malignancy of the male genitourinary system and is one of the leading causes of male cancer death. The P2X7 receptor is an important member of purine receptor family. It is a gated ion channel with adenosine triphosphate (ATP) as the ligand, which exists in a variety of immune tissues and cells and can be involved in tumorigenesis and tumor progression. Studies have shown that the P2X7 receptor is abnormally expressed in prostate cancer, and is related to the level of prostate-specific antigen, P2X7 receptor may be an early biomarker of prostate cancer. The P2X7 receptor is essential in the occurrence and development of prostate cancer. The P2X7 receptor mainly affects the invasion and metastasis of prostate cancer cells through epithelial mesenchymal transition/invasion-related genes and the PI3K/AKT and ERK1/2 signaling pathways. The P2X7 receptor could be a promising therapeutic target for prostate cancer.

Indexed as

Adenosine TriphosphateProstatic NeoplasmsReceptors, Purinergic P2X7HumansMalePhosphatidylinositol 3-KinasesSignal TransductionAdenosine TriphosphateP2RX7 protein, humanPhosphatidylinositol 3-KinasesReceptors, Purinergic P2X7ATPInvasionMetastasisP2X7 receptorProstate cancer

Identifiers

PMID35657562
OpenAlexW4281981432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.